Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome

This study has been completed.
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
First received: February 3, 2006
Last updated: March 17, 2010
Last verified: March 2010

We want to test the hypothesises that patients with nephrotic syndrome have a higher excretion of AQP2 in the urine,that they have a higher concentration of AVP,and a lower C-H2O.Everything will normalize, when the syndrome is in remission.Furthermore we want to test the hypothesis that the expression of mutations in the NPHS2-gene,that codes for podocin,will cause a lack off or a poorer response in the treatment of nephrotic syndrome

Condition Phase
Nephrotic Syndrome
Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome

Further study details as provided by Regional Hospital Holstebro:

Estimated Enrollment: 150
Study Start Date: May 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

adult patients with nephrotic syndrome healthy volunteers


Inclusion Criteria:

adult patients with nephrotic syndrome in the years 1995 until now; both male and female; the kidney disease must be based upon a kidney biopsy ; age > 18 years -

Exclusion Criteria:

severe diseases in the heart, lungs or liver; diabetes mellitus; other not well-treated diseases in endocrine organs; cancer unwillingness to participate


  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00286910

Department of Medicine, Holstebro Hospital
Holstebro, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Study Chair: Erling B Pedersen, professor Holstebro Hospital, Denmark
  More Information

No publications provided

Responsible Party: Holstebro Hospital, Erling Bjerregaard Pedersen
ClinicalTrials.gov Identifier: NCT00286910     History of Changes
Other Study ID Numbers: MED.RES.HOS.2005.05/ IMT
Study First Received: February 3, 2006
Last Updated: March 17, 2010
Health Authority: Denmark: Ethics Committee

Keywords provided by Regional Hospital Holstebro:

Additional relevant MeSH terms:
Nephrotic Syndrome
Stress, Psychological
Kidney Diseases
Urologic Diseases
Behavioral Symptoms

ClinicalTrials.gov processed this record on April 16, 2014